VANCOUVER, British Columbia and MENLO PARK, Calif., June 29, 2017 /PRNewswire/ — DelMar Pharmaceuticals (Nasdaq: DMPI) (“DelMar” and the “Company”), a biopharmaceutical company focused on developing new cancer therapies, announced today that Jeffrey Bacha, Chief Executive Officer and Dennis Brown, Chief Scientific Officer have accepted invitations to join the National Brain Tumor Society’s (NBTS) Research Roundtable.
The inaugural meeting entitled, “Streamlining Clinical Trials to Accelerate Brain Tumor Drug Development,” was held on June 28, 2017 in Washington D.C., and included leaders from the neuro-oncology community and the U.S. FDA. The meeting focused on improving the understanding of how research can better utilize novel endpoints and innovative design to optimize primary brain tumor clinical trials seeking regulatory approval for next generation therapeutic agents.
“Dr. Brown and I are very enthusiastic about the potential of the NBTS Research Roundtable to have a significant impact in the development of new brain tumor treatments,” said Mr. Bacha. It is a privilege to work alongside distinguished researchers, colleagues from the National Brain Tumor Society, and the NCI and FDA toward a common goal of bringing better treatments and cures to patients and families battling and surviving brain cancer.”
Formed in 2008 by the merger of the National Brain Tumor Foundation and the Brain Tumor Society, the National Brain Tumor Society (NBTS) is the largest non-profit organization dedicated to the brain tumor community in the United States. Both organizations had previously been formed in the 1980s by parents and other individuals who wanted to increase both research funding and access to resources specific to brain tumors. NBTS brings together research and public policy to effect change at all levels of the brain tumor research and development system in order to innovate new, and better treatments to patients. In research, NBTS seeks new therapeutic targets, as well as to improve existing treatments, and encourages research that connects directly to patient care and enhances quality of life for all brain tumor patients. NBTS also provides education and information to help patients, families, and caregivers make informed decisions and develop strong support systems.
“As part of the NBTS roundtable, DelMar will gain important alliances and insights to support the advancement of our research to develop new treatments for brain tumor patients. These relationships will be increasingly valuable as we advance VAL-083 into pivotal clinical trials,” added Mr. Bacha.
Connect with the Company on Twitter, LinkedIn, Facebook, and Google+.